effect of vitamin D on Autism Spectrum Disorders

Effect of vitamin D supplementation on core symptoms and serum biomarkers (serotonin and IL-6) in children with autism spectrum disorders

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20131013014994N5

Enrollment

Registered

2018-04-18

Start date

2018-04-20

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

autism spectrum disorders. Autistic disorder

Interventions

Intervention 1: 15 drops of placebo are administered daily for three months. Intervention 2: Daily vitamin D supplements, 300 units per kilogram of body weight, up to a maximum of 6,000 units for thre

Eligibility

Sex/Gender

All

Age

3 Years to 13 Years

Inclusion criteria

Inclusion criteria: The desire for parental collaboration The age range of 3 to 13 years The diagnosis of autism disorder based on DSM-5 criteria

Exclusion criteria

Exclusion criteria: Reluctance to continue cooperation Children with significant hearing loss and vision loss Other neurological disorders such as cerebral palsy, phenylketonuria, seizure disorders History of head trauma, genetic abnormalities, premature children, children with nutritional and malnutrition problems, children with digestive problems, immune disorders, children with endocrine diseases, cardiovascular, pulmonary, kidney, liver Children two months prior to study Supplements or the following medications: vitamin A, vitamin D, fish liver oil, steroids, cimetidine, heparin, diuretics, digoxin, diltiazem and verapamil Children with serum vitamin D levels above 80 ng / ml

Design outcomes

Primary

Measure	Time frame
Severity of autism. Timepoint: At the beginning of the study and 12 weeks after the start of treatment. Method of measurement: By Childhood Autism Rating Scale (CARS) - Aberrant Behavior Checklist-Community (ABC-C) Rating Scale.;Evaluation of autism treatment. Timepoint: At the beginning of the study and 12 weeks after the start of treatment. Method of measurement: By Autism Treatment Evaluation Checklist.;Vitamin D serum level. Timepoint: First and twelfth week of study. Method of measurement: Eliza.;Serotonin serum level. Timepoint: First and twelfth week of study. Method of measurement: Eliza.;Interleukin 6 serum level. Timepoint: First and twelfth week of study. Method of measurement: Eliza.	—

Measure

Time frame

Severity of autism. Timepoint: At the beginning of the study and 12 weeks after the start of treatment. Method of measurement: By Childhood Autism Rating Scale (CARS) - Aberrant Behavior Checklist-Community (ABC-C) Rating Scale.;Evaluation of autism treatment. Timepoint: At the beginning of the study and 12 weeks after the start of treatment. Method of measurement: By Autism Treatment Evaluation Checklist.;Vitamin D serum level. Timepoint: First and twelfth week of study. Method of measurement: Eliza.;Serotonin serum level. Timepoint: First and twelfth week of study. Method of measurement: Eliza.;Interleukin 6 serum level. Timepoint: First and twelfth week of study. Method of measurement: Eliza.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZohreh Javadfar

Kermanshah University of Medical Sciences

zohreh.javadfar@kums.ac.ir+98 83 3828 1991

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026